Table 1.
Baseline patient characteristics and phenotype according to the Montreal Classification of Crohn's disease patients treated with ustekinumab
| Characteristics | N (%) * | N—total |
|---|---|---|
| Median age at baseline, years (IQR) | 40 (31–54) | 114 |
| Sex, female | 54 (47) | 114 |
| BMI–Mean ± SD | 25.4 ± 5.7 | 110 |
| Smoking status | ||
| Current | 12 (11) | 114 |
| Previous | 40 (35) | |
| Never | 62 (54) | |
| Age at diagnosis | ||
| ≤ 16 years (A1) | 17 (15) | 114 |
| 17–40 years (A2) | 75 (66) | |
| < 40 years (A3) | 22 (19) | |
| Location | ||
| Ileum (L1) | 24 (21) | 114 |
| Colon (L2) | 35 (31) | |
| Ileocolonic (L3) | 55 (48) | |
| Behavior | ||
| Inflammatory (B1) | 51 (45) | 114 |
| Stricturing (B2) | 50 (44) | |
| Penetrating (B3) | 13 (11) | |
| Perianal disease (B1p –B3p) | 18 (16) | |
| Any extra intestinal manifestation | 20 (18) | 114 |
| Previous surgical resection | 37 (32) | 114 |
| Previous biological treatment | ||
| ≥ 1 | 107 (94) | 112 |
| ≥ 2 | 58 (51) | |
| ≥ 3 | 24 (21) | |
| Reason for termination of last biological agent | ||
| Lack of or loss of response | 83 (78) | 107 |
| Intolerance | 21 (20) | |
| Other reason | 3 (3) | |
| Concomitant medication at baseline | ||
| Corticosteroids | 21 (18) | 114 |
| Immunomodulators | 26 (23) | |
| HBI Median, (IQR)/Mean ± SD | 6 (4–11)/7.8 ± 5.1 | 96 |
| Clinical disease activity | ||
| Remission (HBI < 5) | 27 (28) | 96 |
| Mild (HBI 5‐7) | 31 (32) | |
| Moderate (HBI 8‐16) | 31 (32) | |
| Severe (HBI ≥ 17) | 7 (7) | |
|
Median f-calprotectin, µg/g (IQR) ≥ 250 µg/g, n (%) |
292 (163–1143) 21 (57) |
37 |
|
Median CRP, mg/l (IQR)/Mean ± SD ≥ 3 mg/l, n (%) |
7 (4–15)/15 ± 20 91 (93) |
98 |
| Median Hb, g/l (IQR)/Mean (SD) | 135 (125–146)/135(16) | 99 |
CRP = C-reactive protein; f-calprotectin = fecal calprotectin; Hb = hemoglobin; HBI = Harvey–Bradshaw Index; IQR = interquartile range; SD = standard deviation
*Number (%) where not otherwise stated